Tisbury Pharmaceuticals is a preclinical-stage pharmaceutical company focused on the discovery, development, and commercialization of treatments for primary open-angle glaucoma. The company's clinical candidate, R-801, accelerates flow through the trabecular meshwork via redox catalysis and K+-ATP channel activation.